Effects of frequency difference, tactile conditions, and replicability. by Farzaneh Darki (22076051)

Cell viability and comparison of cells’ reactive oxygen species (ROS) in stress environments. by Merve Gozel (21982654)

Serum phosphorus level. by Naoki Suzuki (308620)

“…Lanthanum carbonate prescriptions decreased significantly in the tenapanor group and were largely replaced by low-dose tenapanor.…”

Characteristics of the study participants. by Naoki Suzuki (308620)

“…Lanthanum carbonate prescriptions decreased significantly in the tenapanor group and were largely replaced by low-dose tenapanor.…”

Serum albumin level. by Naoki Suzuki (308620)

“…Lanthanum carbonate prescriptions decreased significantly in the tenapanor group and were largely replaced by low-dose tenapanor.…”

Serum calcium levels corrected for albumin. by Naoki Suzuki (308620)

“…Lanthanum carbonate prescriptions decreased significantly in the tenapanor group and were largely replaced by low-dose tenapanor.…”

The proportion of the dosage of tenapanor. by Naoki Suzuki (308620)

“…Lanthanum carbonate prescriptions decreased significantly in the tenapanor group and were largely replaced by low-dose tenapanor.…”

Crystal violet assay. by Takanori Kitagawa (20727226)

“…YCW-H demonstrated significant anti-proliferative effects on MCF7 cells, reducing cell growth by 58.7% ± 6.9 even when physically separated from the cells by a plastic wall. …”

Experiments (Crystal violet assay). by Takanori Kitagawa (20727226)

“…YCW-H demonstrated significant anti-proliferative effects on MCF7 cells, reducing cell growth by 58.7% ± 6.9 even when physically separated from the cells by a plastic wall. …”

Experiments (Crystal violet assay). by Takanori Kitagawa (20727226)

“…YCW-H demonstrated significant anti-proliferative effects on MCF7 cells, reducing cell growth by 58.7% ± 6.9 even when physically separated from the cells by a plastic wall. …”

FCM analysis (%). by Takanori Kitagawa (20727226)

“…YCW-H demonstrated significant anti-proliferative effects on MCF7 cells, reducing cell growth by 58.7% ± 6.9 even when physically separated from the cells by a plastic wall. …”

Experiments (Crystal violet assay). by Takanori Kitagawa (20727226)

“…YCW-H demonstrated significant anti-proliferative effects on MCF7 cells, reducing cell growth by 58.7% ± 6.9 even when physically separated from the cells by a plastic wall. …”

Experiments (Crystal violet assay). by Takanori Kitagawa (20727226)

“…YCW-H demonstrated significant anti-proliferative effects on MCF7 cells, reducing cell growth by 58.7% ± 6.9 even when physically separated from the cells by a plastic wall. …”

ESR Data for by Takanori Kitagawa (20727226)

“…YCW-H demonstrated significant anti-proliferative effects on MCF7 cells, reducing cell growth by 58.7% ± 6.9 even when physically separated from the cells by a plastic wall. …”

Experiments (Crystal violet assay). by Takanori Kitagawa (20727226)

“…YCW-H demonstrated significant anti-proliferative effects on MCF7 cells, reducing cell growth by 58.7% ± 6.9 even when physically separated from the cells by a plastic wall. …”

Live/Dead cells 4 days incubation. by Takanori Kitagawa (20727226)

“…YCW-H demonstrated significant anti-proliferative effects on MCF7 cells, reducing cell growth by 58.7% ± 6.9 even when physically separated from the cells by a plastic wall. …”

ESR Fig 4, Table 1 data. by Takanori Kitagawa (20727226)

“…YCW-H demonstrated significant anti-proliferative effects on MCF7 cells, reducing cell growth by 58.7% ± 6.9 even when physically separated from the cells by a plastic wall. …”

Included studies basic characteristics. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

Forest plot for FVC. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”

All data extracted. by Xuqin Du (8803772)

“…</p><p>Conclusion</p><p>The current evidence suggests that QJHTD, as an adjunct therapy to standard treatment, may significantly improve pulmonary function, reduce inflammatory mediators, and enhance clinical efficacy in patients with stable COPD, with a favorable safety profile. …”